SEER is an authoritative source of information on cancer incidence and survival in the United States. SEER currently collects and publishes cancer incidence and survival data from population-based cancer registries covering approximately 28 percent of the U.S. population.
Bone marrow dysplasia showing refractory macrocytic anemia with oval macrocytes and nonlobulated megakaryocytes. 75% of patients have increased cellularity of marrow. One third of patients have chromosomal abnormality that consists of deletion of the long arm of chromosome 5 (5q). Marrow blasts <5%. Platelet count normal to elevated No Auer rods Normal to increased megakaryocytes
For MDS diseases (9980, 9982, 9983, 9985, 9986, 9989, 9991, 9992), abstracting each of the subtypes would result in over-counting of the diseases. 1. Code only the first subtype that is diagnosed. 2. Do not change the histology code or create a new abstract for any subsequent specific MDS subtypes
Recently the thalidomide analog lenalidomide has been shown to benefit MDS patients. Transfusion independence was achieved in two-thirds of patients.
Definitive Diagnostic Methods
Bone marrow biopsy
Deletion between bands q31 and q33 on chromosome 5